Tests CDR132L against placebo in people with heart failure and an enlarged heart wall
Tests CDR132L, a possible new medicine, in adults with heart failure and thickened heart muscle.
Plain-language title generated from the registry record
Registry title: A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
Key facts
- Where
- Dehradun, Kochi, Ludhiana, Mumbai, Nagpur, New Dehli, New Delhi, and Vadodara, IndiaSee the 9 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 40-84 with long-standing symptomatic heart failure, a weakened heart pump and a thickened or enlarged left heart chamber.
- Age
- 40 to 84 years
- Sex
- All sexes can join.
- Disease stage
- Symptomatic heart failure diagnosed at least 180 days before screening, New York Heart Association class II-III, with a need for water tablets (oral diuretics) at least weekly. Left ventricular ejection fraction below 50%, with a thickened or enlarged left ventricle on heart ultrasound. NT-proBNP of at least 300 pg/mL (at least 600 pg/mL with atrial fibrillation/flutter).
- Earlier treatment
- Must be stable on optimized doses of standard heart failure medicines, with no change in drug classes for at least 45 days before randomisation.
- Biomarker or test result
- NT-proBNP of at least 300 pg/mL, or at least 600 pg/mL if atrial fibrillation/flutter is present. Heart ultrasound measures of the left ventricle (LVMi or LVEDDi above the set limits for women and men).
Main reasons for not taking part
- Severe kidney problems (eGFR below 30) or acute kidney injury within 90 days before randomisation
- Heart attack, unstable angina or hospital stay for heart failure within 30 days before screening
- Stroke or transient ischemic attack within 12 months before randomisation
- Known or suspected genetic cause of a thicker heart muscle, cardiac amyloidosis or sarcoidosis
- Known severe liver disease or liver tests above 2.5 times the upper limit of normal
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 84 years old?
Source: NCT06979375, who can take part
Where in India
- Shri Mahant Indiresh HospitalDehradun, IndiaContact: Novo NordiskTaking people
- Lisie HospitalKochi, IndiaContact: Novo NordiskTaking people
- Dayanand Medical College & HospitalLudhiana, IndiaContact: Novo NordiskTaking people
- Seth GS Medical College & KEM HospitalMumbai, IndiaContact: Novo NordiskTaking people
- Arneja Heart & Multispeciality HospitalNagpur, IndiaContact: Novo NordiskTaking people
- VMMC & Safdarjung HospitalNew Dehli, IndiaContact: Novo NordiskTaking people
- G B Pant Institute of Postgraduate Medical Education and ResearchNew Delhi, IndiaContact: Novo NordiskTaking people
- Sir Ganga Ram Hospital-CardiologyNew Delhi, IndiaContact: Novo NordiskTaking people
- Rhythm heart instituteVadodara, IndiaContact: Novo NordiskTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT06979375EU 2024-515797-27-00
- Record updated
- 11 March 2026
- Original description
This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chance. The study will last for about 60 weeks.Read full original descriptionShow less
Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chance. The study will last for about 60 weeks.
Inclusion: Age 40-84 years (both inclusive) at the time of signing the informed consent; Documented symptomatic heart failure (HF) diagnosed greater than or equal to (≥) 180 days prior to screening with at least weekly need for oral diuretic treatment, and New York Heart Association class II-III at screening; Clinically stable and on optimized doses and unchanged drug classes of guideline-directed HF therapy ≥ 45 days prior to randomisation; Left ventricular ejection fraction (LVEF) less than (<) 50 percent (%) as assessed by echocardiography at screening, measured by central laboratory; Left ventricular hypertrophy or left ventricular dilatation assessed by echocardiography at screening measured by central laboratory with any of the following:; LVMi greater than (>)88 g/m\^2 for female participants and >102 g/m\^2 for male participants using the truncated ellipsoid method; LVMi >95 g/m\^2 for female participants and >115 g/m\^2 for male participants, using the linear method (cube formula); Left ventricular end-diastolic diameter indexed to body surface area (LVEDDi) >3.1 cm/m\^2 for female participants and >3.0 cm/m\^2 for male participants; Body mass index 18.5-40 kilogram per meter square (kg/m\^2) (both inclusive) and body weight less than or equal to (≤) 140 kilogram (kg). Body mass index is calculated in the electronic case report form based on height and body weight at the screening visit (visit 1); N-terminal pro B-type natriuretic peptide (NT-proBNP) ≥ 300 picograms per milliliter (pg/mL); NT-proBNP ≥600 pg/mL if atrial fibrillation/flutter is present at time of screening, measured by central laboratory.
Exclusion: Participants with an episode of acute kidney failure or acute kidney injury, at the discretion of the investigator,within 90 days prior to randomisation; Myocardial infarction, unstable angina pectoris or HF hospitalization within 30 days prior to screening; Participants receiving intravenous HF medications within 45 days prior to randomisation; Stroke or transient ischemic attack within 12 months prior to randomisation; Planned coronary revascularization, pacemaker/cardioverter-defibrillator/cardiac resynchronization therapy (CRT) implantation, ablation of cardiac arrythmias or valve repair/replacement at the time of randomisation; Known genetic (or highly suspected due to family history) cause of increased cardiac mass (including dilated cardiomyopathy, Fabry disease and likely pathogenic or pathogenic variants within hypertrophic cardiomyopathy (HCM); Participants with suspected or diagnosed cardiac amyloidosis or sarcoidosis; Estimated Glomerular Filtration Rate (eGFR) less than (<) 30 milliliter/minute/ 1.73-meter square (mL/min/1.73 m\^2) at time of screening, measured by central laboratory; Known history of severe liver disease and/or alanine aminotransferase or aspartate aminotransferase greater than (>) 2.5x upper limit of normal at screening, measured by central laboratory; Participants with potential disruption of the blood-brain barrier (e.g., multiple sclerosis), in the opinion of the investigator.